Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Geron Corp. -- Ignore unavailable to you. Want to Upgrade?

To: Howard H Bouch who wrote (1952)	11/27/1998 7:19:00 PM
From: Bald Man from Mars	Respond to of 3576

I have no inside information regarding the rise ... may be someone slip him a dose or two of Viagra in his morning coffee ...

To: Howard H Bouch who wrote (1952)	11/27/1998 9:15:00 PM
From: HiSpeed	Respond to of 3576

This maybe the reason; however, if it is I'd expect the stock to go down as quick cuz it really doesn't add anything new-just reinforces the value of the original discovery. There could be news pending, too. The only thing out of synch is that this release was out 6am this morning. The way GERN shares took off, I'd suspect something else is up. Here's the release: Stem Cells 'Grow' in Value Potential Benefits of Umbilical Cord Banking Further Validated SAN BRUNO, Calif., Nov. 27 /PRNewswire/ -- On the heels of recent reports that scientists have discovered possible future technology that may enable doctors to grow entire organs to replace diseased ones using stem cells; a study appearing in the New England Journal of Medicine is reinforcing the value and use of cord blood stem cells in current medical treatment. The study released in yesterday's New England Journal of Medicine (NEJM) provides further affirmation for the thousands of expectant parents collecting and cryo-preserving their child's umbilical cord blood as a type of ''biological insurance'' for potential future use by their family in treating serious cancers and immune system disorders. Previously discarded, cord blood is collected from the umbilical cord when a baby is born, and has been used to treat more than 30 diseases since it was discovered to contain stem cells, the cells that create the vital components of blood and the immune system. Until recently, bone marrow was the only known source of stem cells for treatment. Umbilical cord blood can be easily collected and banked for potential future use, avoiding the long donor search some families endure when they require stem cells for treatment. Cord blood has been used in more than 1,500 transplants in both adults and children. This NEJM study of 562 recipients is evidence of the significant increase in research and funds invested in the field of cord blood transplantation and stem cell therapy. The worldwide consortium of doctors who authored the NEJM study denotes the global commitment to the growth of use of cord blood in the medical industry. Cell expansion technologies are catalyzed by this type of study, and some researchers believe that acquiring stem cells from bone marrow could eventually be a thing of the past. Additional clinical studies indicate that cord blood from a family member provides double the survival rate of cord blood from an unrelated donor when used in transplant, and at Cord Blood Registry (CBR), 97% of the families who bank with the company say they do so because it gives them peace of mind. CBR is the nation's largest family umbilical cord blood bank and administers 888-CORD BLOOD, a toll-free information and counseling line. CBR currently has more than 10,000 family banked samples and has processed and banked more stem cells than any other facility in the world. SOURCE: Cord Blood Registry